 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 3 | 1/1 | 返回列表 |
| 查看: 532 | 回復(fù): 2 | ||
liujiashen木蟲 (正式寫手)
|
[求助]
高分求高手幫助翻譯文章
|
|
Pharmacokinetics Non-clinical pharmacokinetic studies were conducted mainly in Wistar rats and dogs. Toxicokinetic data were collected from repeated dose studies in mice (CD-1), rats, dogs and female rabbits. General organ distribution was studied in Wistar rats and pigmented rats; placental transfer and excretion into milk was studied in female Wistar rats. Plasma protein binding and metabolism were investigated in vitro in several species, including Cynomolgus monkeys and humans. Several in vitro studies were conducted to characterise the involvement, inhibition and induction of cytochrome Ps (CYPs), P-gp and Bcrp. Finally, cell permeability was studied in Caco-2 cells. Absorption after a single oral dose of rivaroxaban was rapid in both rats and dogs with maximal plasma concentration achieved in about 0.5 hours. The extent of absorption was somewhat lower in rats (67%) than in dogs (92%). After repeat dosing for 4 weeks, there was an increased absorption in rats, but not in mice or dogs. Higher exposure was observed in the female rats. Protein binding varied between species, highest being in rat (98.7%) and lowest in rabbit (76.6%). Mechanistic studies showed that serum albumin is the main binding protein. However, a mechanistic study with human serum albumin (HSA) and oleic acid showed a striking difference in protein binding depending on the oleic acid concentration. This difference in protein binding is large enough to cover almost the entire range observed in different species. Organ distribution after a single oral dose of rivaroxaban shows highest concentrations in the gastro- intestinal tract, liver and kidneys, lower concentrations in the brain. Rivaroxaban showed minor affinity to melanin-containing tissues, such as pigmented skin areas and eyes. After repeated oral administration to rats (14 consecutive daily administrations), radioactivity showed a moderate accumulation tendency. A slow elimination of rivaroxaban and its metabolites from bone after repeated dosing raised a suspicion of a potential connection with skeletal malformations observed in the reproductive toxicity studies. However, the detailed review of the data revealed that the absolute retention in bone is unlikely to prolong exposure and thus cause adverse effects on skeleton. Nevertheless, the embryotoxic observation (see section on Toxicology) remains and is addressed in the SPC. Volume of distribution was moderate, amounting to 0.3 L/kg for the rat and to 0.4 L/kg for the dog. Rivaroxaban was eliminated from rat and dog plasma with half-lives between 1 and 2 h. Rivaroxaban passes through the placental barrier but does not accumulate in the foetuses. In rats, the substance is excreted in milk. Rivaroxaban is subject to oxidative metabolism in liver. The in vivo biotransformation pathways of rivaroxaban in man are similar to those in animals and are reflected in the in vitro investigation with liver microsomes and cultured hepatocytes from different species. The main metabolic pathway, the oxidative degradation of the morpholinone moiety, was catalyzed by CYP3A4/3A5 and CYP2J2 and lead via cleavage of the ring and further oxidation to the formation of metabolite M1. Another pathway is the hydrolysis of the amide bond, generating metabolites M15 and M13. Besides unchanged rivaroxaban, metabolite M1 was identified as main metabolite in the excreta of animals and man. Qualitatively, the animal metabolism of rivaroxaban is similar to that of man and there are no unique human metabolites. There are quantitative differences but none of them represent a cause for concern. Elimination of rivaroxaban from plasma was rapid with no major circulating metabolites detected in plasma of rat, dog, and man. The main excretion routes in the investigated animal species and in man were renal and faecal/biliary. The rat differs from dogs and humans by a higher proportion of rivaroxaban and metabolites excreted in bile/faeces, and a lower proportion excreted in urine. |
回復(fù)此樓» 猜你喜歡
086502化學(xué)工程342求調(diào)劑
已經(jīng)有4人回復(fù)
-
材料求調(diào)劑一志愿哈工大324
已經(jīng)有7人回復(fù)
-
328求調(diào)劑
已經(jīng)有7人回復(fù)
-
340求調(diào)劑
已經(jīng)有5人回復(fù)
-
一志愿南昌大學(xué)324求調(diào)劑
已經(jīng)有4人回復(fù)
-
求調(diào)劑推薦 材料 304
已經(jīng)有15人回復(fù)
-
291求調(diào)劑
已經(jīng)有19人回復(fù)
-
331環(huán)境科學(xué)與工程求調(diào)劑
已經(jīng)有3人回復(fù)
-
289求調(diào)劑
已經(jīng)有8人回復(fù)
-
315分求調(diào)劑
已經(jīng)有7人回復(fù)
fjtony163
版主 (文壇精英)
米米
- 翻譯EPI: 386
- 應(yīng)助: 361 (碩士)
- 貴賓: 6.876
- 金幣: 70610.6
- 散金: 36050
- 紅花: 222
- 沙發(fā): 616
- 帖子: 21912
- 在線: 3793.7小時(shí)
- 蟲號(hào): 1397876
- 注冊(cè): 2011-09-11
- 專業(yè): 遺傳學(xué)研究新技術(shù)與方法
- 管轄: 論文翻譯
2樓2013-06-25 10:37:42
liujiashen
木蟲 (正式寫手)
- 應(yīng)助: 9 (幼兒園)
- 金幣: 1953.7
- 紅花: 3
- 帖子: 499
- 在線: 178.3小時(shí)
- 蟲號(hào): 1120936
- 注冊(cè): 2010-10-12
- 性別: GG
- 專業(yè): 藥劑學(xué)
3樓2013-06-27 07:59:17
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 liujiashen 的主題更新
| 3 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 328求調(diào)劑 +7 | 嗯滴的基本都 2026-03-27 | 7/350 |
|
|---|---|---|---|---|
|
|
[考研] 291求調(diào)劑 +13 | hhhhxn.. 2026-03-23 | 19/950 |
|
|
|
[考研] 289求調(diào)劑 +8 | 新時(shí)代材料 2026-03-27 | 8/400 |
|
|
|
[考研] 295求調(diào)劑 +5 | 1428151015 2026-03-27 | 6/300 |
|
|
|
[考研] 291求調(diào)劑 +7 | 孅華 2026-03-22 | 7/350 |
|
|
[材料工程] 一志愿C9材料與化工專業(yè)總分300求調(diào)劑 +7 | 曼111 2026-03-24 | 8/400 |
|
|
|
[考研] 085601 材料工程 313分 求調(diào)劑 +5 | Ong3 2026-03-27 | 5/250 |
|
|
|
[考研] 303求調(diào)劑 +7 | 安憶靈 2026-03-22 | 8/400 |
|
|
|
[考研] 333求調(diào)劑 +3 | question挽風(fēng) 2026-03-23 | 3/150 |
|
|
|
[考研] 314求調(diào)劑 +3 | 溪云珂 2026-03-26 | 3/150 |
|
|
|
[考研] 0703化學(xué)一志愿南京師范大學(xué)303求調(diào)劑 +3 | zzffylgg 2026-03-24 | 3/150 |
|
|
|
[考研] 333求調(diào)劑 +7 | 87639 2026-03-21 | 12/600 |
|
|
|
[考研] 材料277求調(diào)劑 +5 | min3 2026-03-24 | 5/250 |
|
|
|
[考研] 318求調(diào)劑 +3 | plum李子 2026-03-23 | 3/150 |
|
|
|
[考研] 300分，材料，求調(diào)劑，英一數(shù)二 +5 | 超贊的 2026-03-24 | 5/250 |
|
|
|
[考研] 305分求調(diào)劑（食品工程） +5 | Sxy112 2026-03-21 | 7/350 |
|
|
|
[考研] 384求調(diào)劑 +3 | 子系博 2026-03-22 | 6/300 |
|
|
|
[考研] 接收2026碩士調(diào)劑(學(xué)碩+專碩) +4 | allen-yin 2026-03-23 | 6/300 |
|
|
|
[考研] 315分，誠(chéng)求調(diào)劑，材料與化工085600 +3 | 13756423260 2026-03-22 | 3/150 |
|
|
|
[考研] 275求調(diào)劑 +6 | shansx 2026-03-22 | 8/400 |
|